Ultragenyx Pharmaceutical Inc

NASDAQ: RARE
$41.53
-$0.34 (-0.8%)
Closing price May 20, 2024

RARE Chart and Intraday Price

RARE Company Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector LIFE SCIENCES
Industry PHARMACEUTICAL PREPARATIONS
Address 60 LEVERONI COURT, NOVATO, CA, US
Fiscal Year End December
Latest Quarter 12/31/2023
Market Cap 4,420.60M USD
Shares Outstanding 82,336,000
Ultragenyx Pharmaceutical Inc is a pioneering biopharmaceutical firm dedicated to advancing healthcare for those facing rare and ultra-rare genetic diseases globally. With a portfolio that includes Crysvita for X-linked hypophosphatemia, Mepsevii for Mucopolysaccharidosis VII, Dojolvi for long-chain fatty acid oxidation disorders, and Evkeeza for homozygous familial hypercholesterolemia, Ultragenyx is at the forefront of developing innovative treatments. Additionally, the company is exploring gene therapies and monoclonal antibodies for various genetic conditions, demonstrating its commitment to transforming patient lives through science. Founded in 2010 and based in Novato, California, Ultragenyx collaborates with leading healthcare and research institutions to fulfill its mission.

RARE Articles

Wednesday's top analyst upgrades and downgrades included Allstate, Archer Daniels Midland, Avis Budget, Baidu, Centene, Lemonade, Melco Resorts & Entertainment, Palantir Technologies, Peabody Energy,...
Wednesday's top analyst upgrades and downgrades included Advanced Micro Devices, Apple, AT&T, Cenovus Energy, Dollar General, Dynatrace, FedEx, Molson Coors Beverage, NiSource, Uber Technologies and...
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's,...
Friday's top analyst upgrades and downgrades included AMC Entertainment, CNH Industrial, Kala Pharmaceuticals, Opendoor Technologies, Tesla and TG Therapeutics.
Thursday's additional analyst upgrades and downgrades were on Alkermes, Altice USA, Fisker, Freshpet, Lincoln National, Maravai LifeSciences and more.
Friday's top analyst upgrades and downgrades included Altice USA, Apple, Colgate-Palmolive, Marathon Petroleum, Mastercard, Medtronic, Meta Platforms, Nike, Prologis, Realty Income, SLM, Tenaris and...
Tuesday's top analyst upgrades and downgrades included Canopy Growth, Constellation Brands, Equifax, FedEx, Franklin Resources, Micron Technology, Paramount Global, RH and T-Mobile.
Wednesday afternoon's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.
Friday afternoon's top analyst upgrades and downgrades included Affirm, AstraZeneca, Block, CVS, Kellogg and more.
Biotechnology was a huge laggard last year, but Truist Securities is out with its five top picks for 2022 that could see some sensational performance this year. Portfolio managers favor these...
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including Nvidia, SeaWorld, Wells Fargo and Zoom Video.
Tuesday’s top analyst upgrades and downgrades included Coursera, CSX, Carvana, FedEx, Fox, Marathon, Petro China, Planet Fitness, Regeneron and Rackspace.
Analyst upgrades and downgrades seen Friday afternoon were on Capital One, Diageo, Wells Fargo and more.
24/7 Wall St. looks at some big analyst calls that we have seen so far on Thursday, including Allstate, Booking, CyberArk and Hilton.
The Christmas Eve top analyst upgrades and downgrades included Baidu, Fiserv, Virgin Galactic and Ultragenyx Pharmaceuticals.